GI Oncology Now

Nataliya Uboha, MD, PhD, of University of Wisconsin School of Medicine and Public Health, and Christopher Lieu, MD, of University of Colorado Medicine, highlight a recent analysis of the KRYSTAL-1 trial.

The study assessed the utility of adagrasib, a selective KRASG12C-inhibitor, in combination with cetuximab, an an anti-EGFR antibody, for the treatment of patients with KRASG12C-mutated metastatic colorectal cancer.

In this special episode of Healthcare Unfiltered, Dr. Tanios Bekaii-Saab, of the Mayo Clinic, joins Dr. Chadi Nabhan to discuss the most groundbreaking studies unveiled at the 2024 ASCO GI Symposium, including an examination of the crucial, previously reported data from IMbrave050 and EMERALD-1.